Clearbridge Investments LLC Has $265.54 Million Holdings in argenx SE (NASDAQ:ARGX)

Clearbridge Investments LLC grew its position in shares of argenx SE (NASDAQ:ARGX) by 3.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 617,466 shares of the company’s stock after buying an additional 21,189 shares during the quarter. Clearbridge Investments LLC owned approximately 1.04% of argenx worth $265,535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in ARGX. Price T Rowe Associates Inc. MD boosted its holdings in argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after purchasing an additional 1,830,651 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of argenx by 24.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after acquiring an additional 439,889 shares in the last quarter. Capital World Investors increased its holdings in shares of argenx by 37.0% during the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after acquiring an additional 530,181 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of argenx by 0.3% during the 1st quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock valued at $487,609,000 after acquiring an additional 3,900 shares during the last quarter. Finally, RTW Investments LP raised its stake in shares of argenx by 31.5% in the 4th quarter. RTW Investments LP now owns 667,195 shares of the company’s stock valued at $253,821,000 after acquiring an additional 160,000 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ARGX. Stifel Nicolaus upped their price objective on shares of argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, June 24th. JPMorgan Chase & Co. boosted their price objective on shares of argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Wedbush lifted their target price on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Piper Sandler upped their price target on argenx from $522.00 to $535.00 and gave the company an “overweight” rating in a report on Monday, June 24th. Finally, William Blair reissued a “market perform” rating on shares of argenx in a report on Monday, June 17th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $547.74.

argenx Stock Up 1.0 %

NASDAQ:ARGX opened at $547.28 on Wednesday. The firm has a market cap of $32.53 billion, a PE ratio of -96.69 and a beta of 0.62. The company’s 50-day moving average price is $520.67 and its two-hundred day moving average price is $439.33. argenx SE has a 12 month low of $327.73 and a 12 month high of $554.74.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The business had revenue of $489.43 million for the quarter, compared to analyst estimates of $436.66 million. During the same period in the prior year, the company earned ($1.69) EPS. On average, research analysts expect that argenx SE will post -0.37 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.